The initial success of Sildenafil undeniably transformed the drug landscape, but investing in companies primarily reliant on porn off-patent versions presents a challenging picture. Although early returns were significant, the cessation of patents and the rise of cheaper alternatives have diminished sales. Thus, a thorough analysis of present incom